Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
PhD Program in Drug Discovery and Development, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
J Med Chem. 2023 Oct 12;66(19):13665-13683. doi: 10.1021/acs.jmedchem.3c01030. Epub 2023 Aug 10.
Less studied than the other protein arginine methyltransferase isoforms, PRMT7 and PRMT9 have recently been identified as important therapeutic targets. Yet, most of their biological roles and functions are still to be defined, as well as the structural requirements that could drive the identification of selective modulators of their activity. We recently described the structural requirements that led to the identification of potent and selective PRMT4 inhibitors spanning both the substrate and the cosubstrate pockets. The reanalysis of the data suggested a PRMT7 preferential binding for shorter derivatives and prompted us to extend these structural studies to PRMT9. Here, we report the identification of the first potent PRMT7/9 inhibitor and its binding mode to the two PRMT enzymes. Label-free quantification mass spectrometry confirmed significant inhibition of PRMT activity in cells. We also report the setup of an effective AlphaLISA assay to screen small molecule inhibitors of PRMT9.
与其他蛋白精氨酸甲基转移酶同工型相比,PRMT7 和 PRMT9 的研究较少,最近被确定为重要的治疗靶点。然而,它们的大多数生物学作用和功能仍有待确定,以及可能导致其活性选择性调节剂识别的结构要求。我们最近描述了导致鉴定出强效和选择性 PRMT4 抑制剂的结构要求,这些抑制剂既涵盖了底物口袋,也涵盖了共底物口袋。对数据的重新分析表明,PRMT7 对较短的衍生物具有优先结合性,并促使我们将这些结构研究扩展到 PRMT9。在这里,我们报告了第一个强效的 PRMT7/9 抑制剂的鉴定及其与两种 PRMT 酶的结合模式。无标记定量质谱法证实了该抑制剂对细胞中 PRMT 活性的显著抑制作用。我们还报告了建立一种有效的 AlphaLISA 测定法来筛选 PRMT9 的小分子抑制剂。